Bicycle Therapeutics Stock (NASDAQ: BCYC)

Bicycle Therapeutics

BICYCLE THERAPEUTICS PLC-ADR

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Why It Matters

News

Price Target

Markets

Analyst Ratings

Trading Ideas

ACHR

AMZN

BCYC

CHCT

FDMT

GOOGL

TRGP

TSLA

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Pre-Market Outlook

Movers

ALMS

CADL

CECO

EGHT

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Biotech

Health Care

General

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.

Bicycle Therapeutics Lead Cancer Drug Combined With Merck&#39;s Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics PLC

Press Releases

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025

Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results

Akebia Therapeutics

AnaptysBio

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Keros Therapeutics

Kura Oncology

MeiraGTx Hldgs

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Replimune Group

Regulus Therapeutics

Relay Therapeutics

Sage Therapeutics

Sionna Therapeutics

Stoke Therapeutics

Savara

Tyra Biosciences

Upstream Bio

Valneva

Xencor

Morgan Stanley

RBC Capital

B. Riley Securities

JMP Securities

Needham

Comments

Bicycle Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell